Back | Next |
home / stock / heb / heb message board
Subject | By | Source | When |
---|---|---|---|
Fully funded trial up to 45-people, low float, | bleu22 | investorshub | 06/16/2019 7:56:04 PM |
Going higher | cspratt15139 | investorshub | 06/16/2019 12:10:39 AM |
LOL..Can't even wait a few days to reward | 420man | investorshub | 06/13/2019 10:49:07 PM |
They dont even have options laid out yet. WTF | bleu22 | investorshub | 06/13/2019 1:37:18 AM |
News: $HEB Hemispherx Biopharma Announces First Patient Treated | whytestocks | investorshub | 06/12/2019 8:00:54 PM |
There's your RS... Let the shorting begin!!! | 420man | investorshub | 06/11/2019 4:11:29 PM |
Split coming | cspratt15139 | investorshub | 06/10/2019 11:30:37 PM |
.05 | 420man | investorshub | 06/07/2019 10:31:37 PM |
How low will it go before the RS | Golden Cross | investorshub | 06/02/2019 8:42:26 AM |
News: $HEB Hemispherx Biopharma Stockholders Approve Reverse Stock Split | whytestocks | investorshub | 05/31/2019 2:30:39 PM |
When is the rs | cspratt15139 | investorshub | 05/29/2019 10:56:58 AM |
https://www.mrknewsroom.com/news-release/oncology/merck-provides-update-phase-3- | hebbeke47 | investorshub | 05/21/2019 8:02:56 AM |
They have investors after the rs or people | carldfw | investorshub | 05/19/2019 12:20:20 AM |
$HEB Daily Chart: | Golden Cross | investorshub | 05/17/2019 11:10:03 PM |
News: $HEB Hemispherx Links Stanford's ME/CFS Diagnostic to | whytestocks | investorshub | 05/06/2019 1:50:39 PM |
$HEB on High Alert | Golden Cross | investorshub | 05/06/2019 1:10:15 PM |
WOW that's insane!!!! Thanks for sharing the actual | tknuncle | investorshub | 05/04/2019 12:53:08 AM |
So the warrant exercise price has been reduced | 420man | investorshub | 05/03/2019 11:41:19 PM |
As I said several times, no value here, | pberger | investorshub | 05/03/2019 11:56:51 AM |
* * $HEB Video Chart 05-02-2019 * * | ClayTrader | investorshub | 05/02/2019 8:41:54 PM |
News, Short Squeeze, Breakout and More Instantly...
Hemispherx BioPharma Inc. Company Name:
HEB Stock Symbol:
NYSE Market:
Hemispherx BioPharma Inc. Website:
OCALA, Fla., Aug. 23, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-tech company focused on the research and development of immunological agents to treat multiple types of cancers and immune-deficiency diseases, such as myalgic encephalomyelitis/chronic...
OCALA, Fla., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announces the filing of its report 10Q for the ...
OCALA, Fla., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American: HEB ) announced today that the University of Pittsburgh Medical Center (UPMC) has issued a final report supporting the safety of using Ampligen in combination therapy for the treatment of recurrent ovar...